Standard Silicone-based vs. B-Lite® Light Weight Breast Implant After Total Mastectomy and Radiotherapy for Breast Cancer
Launched by ISTITUTI CLINICI SCIENTIFICI MAUGERI SPA · Nov 8, 2018
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Breast cancer diagnosis with indication of total mastectomy and breast reconstruction
- • Indication of post-mastectomy radiation therapy
- • Availability to be followed up for 24 months
- • Signature of informed consent
- Exclusion Criteria:
- • Patients candidated to breast-conserving surgery
- • Contraindicated breast reconstruction (severe comorbidities, unfavourable survival outcome expected, distant metastases)
- • Patients affected by other solid malignancies
- • Pregnancy
- • Participation to other clinical studies in the last three months
About Istituti Clinici Scientifici Maugeri Spa
Istituti Clinici Scientifici Maugeri S.p.A. is a prestigious Italian healthcare organization dedicated to advancing medical research and clinical practice. With a strong focus on patient-centered care, the institution integrates innovative clinical trials into its comprehensive services, fostering collaboration between researchers and healthcare professionals. Known for its commitment to high-quality standards and ethical practices, Istituti Clinici Scientifici Maugeri S.p.A. plays a pivotal role in the development of new therapies and treatment modalities, contributing significantly to the global medical community and enhancing patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, , Italy
Patients applied
Trial Officials
Fabio Corsi, MD
Principal Investigator
Istituti Clinici Scientifici Maugeri Spa SB
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials